Shots:
The US FDA has approved Outlook’s Lytenava (Bevacizumab-vikg) for wet AMD
Bevacizumab-vikg (bevacizumab gamma in the EU and UK) is a recombinant humanized IgG1 MAb targeting VEGF
Additionally, the approval is expected to provide LYTENAVA with 12 years of Reference Product Exclusivity under the BPCIA
Ref: Outlook Therapeutics | Image: Outlook Therapeutics | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications.…
